カテゴリ： 世界, 医療/バイオ, QYResearch

腫瘍免疫治療の世界市場2023年：免疫チェックポイント阻害剤、サイトカイン免疫療法、がんワクチン、Car-t細胞療法、その他

■ 英語タイトル：Global Tumor Immunity Therapy Market Research Report 2023

調査会社QYResearch社が発行したリサーチレポート（データ管理コード：QYR23MA8914）■ 発行会社/調査会社：QYResearch
■ 商品コード：QYR23MA8914
■ 発行日：2023年3月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：101
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,900 ⇒換算￥440,800見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD4,350 ⇒換算￥661,200見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD5,800 ⇒換算￥881,600見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[腫瘍免疫治療の世界市場2023年：免疫チェックポイント阻害剤、サイトカイン免疫療法、がんワクチン、Car-t細胞療法、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査資料は腫瘍免疫治療のグローバル市場について調査・分析し、世界の腫瘍免疫治療市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（免疫チェックポイント阻害剤、サイトカイン免疫療法、がんワクチン、Car-t細胞療法、その他）、用途別セグメント分析（病院、クリニック）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Bristol-Myers Squibb、Merck & Co., Inc.、Roche AG、AstraZeneca, Plc、Sanofi S.A.、Dendreon Pharmaceuticals、Novartis、Gilead Sciences Inc.、IMVAQ Therapeutics、Arch Oncology、Juno Therapeutics、Refuge、Lepu Biopharma、Genoimmune、TCR Cureなどが含まれています。腫瘍免疫治療のグローバル市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。新型コロナとロシア・ウクライナ戦争の影響は、腫瘍免疫治療市場規模を算出する際に考慮しました。

・腫瘍免疫治療市場の概要
- 腫瘍免疫治療の種類別セグメント
- 世界の腫瘍免疫治療市場規模：タイプ別分析（免疫チェックポイント阻害剤、サイトカイン免疫療法、がんワクチン、Car-t細胞療法、その他）
- 腫瘍免疫治療の用途別セグメント
- 世界の腫瘍免疫治療市場規模：用途別分析（病院、クリニック）
- 世界の腫瘍免疫治療市場規模予測（2018年-2029年）

・腫瘍免疫治療市場の成長トレンド
- 腫瘍免疫治療の地域別市場規模（2018年-2029年）
- 腫瘍免疫治療市場ダイナミクス
- 腫瘍免疫治療の業界動向
- 腫瘍免疫治療市場の成長ドライバ、課題、阻害要因

・主要企業別競争状況
- 企業別市場シェア
- 世界の主要企業、業界ランキング分析
- 市場への参入、M＆A動向

・種類別セグメント：免疫チェックポイント阻害剤、サイトカイン免疫療法、がんワクチン、Car-t細胞療法、その他
- 世界の腫瘍免疫治療のタイプ別市場規模（2018年-2023年）
- 世界の腫瘍免疫治療のタイプ別市場規模（2024年-2029年）

・用途別セグメント：病院、クリニック
- 世界の腫瘍免疫治療の用途別市場規模（2018年-2023年）
- 世界の腫瘍免疫治療の用途別市場規模（2024年-2029年）

・腫瘍免疫治療の地域別市場規模
- 北米の腫瘍免疫治療市場規模（2018年-2029年）
- 米国の腫瘍免疫治療市場規模（2018年-2029年）
- ヨーロッパの腫瘍免疫治療市場規模（2018年-2029年）
- アジア太平洋の腫瘍免疫治療市場規模（2018年-2029年）
- 中国の腫瘍免疫治療市場規模（2018年-2029年）
- 日本の腫瘍免疫治療市場規模（2018年-2029年）
- 韓国の腫瘍免疫治療市場規模（2018年-2029年）
- インドの腫瘍免疫治療市場規模（2018年-2029年）
- オーストラリアの腫瘍免疫治療市場規模（2018年-2029年）
- 中南米の腫瘍免疫治療市場規模（2018年-2029年）
- 中東・アフリカの腫瘍免疫治療市場規模（2018年-2029年）

・主要企業のプロファイル：企業情報、事業概要、売上、動向
Bristol-Myers Squibb、Merck & Co., Inc.、Roche AG、AstraZeneca, Plc、Sanofi S.A.、Dendreon Pharmaceuticals、Novartis、Gilead Sciences Inc.、IMVAQ Therapeutics、Arch Oncology、Juno Therapeutics、Refuge、Lepu Biopharma、Genoimmune、TCR Cure

・アナリストの観点/結論

・調査手法と情報源

Highlights
The global Tumor Immunity Therapy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Tumor Immunity Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Tumor Immunity Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Tumor Immunity Therapy in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Tumor Immunity Therapy include Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc. and IMVAQ Therapeutics, etc. In 2022, the world’s top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Tumor Immunity Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Tumor Immunity Therapy.
The Tumor Immunity Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Tumor Immunity Therapy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Tumor Immunity Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Bristol-Myers Squibb
Merck & Co., Inc.
Roche AG
AstraZeneca, Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
IMVAQ Therapeutics
Arch Oncology
Juno Therapeutics
Refuge
Lepu Biopharma
Genoimmune
TCR Cure
Segment by Type
Immune Checkpoint Inhibitor
Cytokine Immunotherapy
Cancer Vaccine
Car-t Cell Therapy
Others
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Tumor Immunity Therapy companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tumor Immunity Therapy Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Immune Checkpoint Inhibitor
1.2.3 Cytokine Immunotherapy
1.2.4 Cancer Vaccine
1.2.5 Car-t Cell Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Tumor Immunity Therapy Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tumor Immunity Therapy Market Perspective (2018-2029)
2.2 Tumor Immunity Therapy Growth Trends by Region
2.2.1 Global Tumor Immunity Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Tumor Immunity Therapy Historic Market Size by Region (2018-2023)
2.2.3 Tumor Immunity Therapy Forecasted Market Size by Region (2024-2029)
2.3 Tumor Immunity Therapy Market Dynamics
2.3.1 Tumor Immunity Therapy Industry Trends
2.3.2 Tumor Immunity Therapy Market Drivers
2.3.3 Tumor Immunity Therapy Market Challenges
2.3.4 Tumor Immunity Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tumor Immunity Therapy Players by Revenue
3.1.1 Global Top Tumor Immunity Therapy Players by Revenue (2018-2023)
3.1.2 Global Tumor Immunity Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Tumor Immunity Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Tumor Immunity Therapy Revenue
3.4 Global Tumor Immunity Therapy Market Concentration Ratio
3.4.1 Global Tumor Immunity Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumor Immunity Therapy Revenue in 2022
3.5 Tumor Immunity Therapy Key Players Head office and Area Served
3.6 Key Players Tumor Immunity Therapy Product Solution and Service
3.7 Date of Enter into Tumor Immunity Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Tumor Immunity Therapy Breakdown Data by Type
4.1 Global Tumor Immunity Therapy Historic Market Size by Type (2018-2023)
4.2 Global Tumor Immunity Therapy Forecasted Market Size by Type (2024-2029)
5 Tumor Immunity Therapy Breakdown Data by Application
5.1 Global Tumor Immunity Therapy Historic Market Size by Application (2018-2023)
5.2 Global Tumor Immunity Therapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Tumor Immunity Therapy Market Size (2018-2029)
6.2 North America Tumor Immunity Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Tumor Immunity Therapy Market Size by Country (2018-2023)
6.4 North America Tumor Immunity Therapy Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tumor Immunity Therapy Market Size (2018-2029)
7.2 Europe Tumor Immunity Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Tumor Immunity Therapy Market Size by Country (2018-2023)
7.4 Europe Tumor Immunity Therapy Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Tumor Immunity Therapy Market Size (2018-2029)
8.2 Asia-Pacific Tumor Immunity Therapy Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Tumor Immunity Therapy Market Size by Region (2018-2023)
8.4 Asia-Pacific Tumor Immunity Therapy Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Tumor Immunity Therapy Market Size (2018-2029)
9.2 Latin America Tumor Immunity Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Tumor Immunity Therapy Market Size by Country (2018-2023)
9.4 Latin America Tumor Immunity Therapy Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tumor Immunity Therapy Market Size (2018-2029)
10.2 Middle East & Africa Tumor Immunity Therapy Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Tumor Immunity Therapy Market Size by Country (2018-2023)
10.4 Middle East & Africa Tumor Immunity Therapy Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Detail
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Tumor Immunity Therapy Introduction
11.1.4 Bristol-Myers Squibb Revenue in Tumor Immunity Therapy Business (2018-2023)
11.1.5 Bristol-Myers Squibb Recent Development
11.2 Merck & Co., Inc.
11.2.1 Merck & Co., Inc. Company Detail
11.2.2 Merck & Co., Inc. Business Overview
11.2.3 Merck & Co., Inc. Tumor Immunity Therapy Introduction
11.2.4 Merck & Co., Inc. Revenue in Tumor Immunity Therapy Business (2018-2023)
11.2.5 Merck & Co., Inc. Recent Development
11.3 Roche AG
11.3.1 Roche AG Company Detail
11.3.2 Roche AG Business Overview
11.3.3 Roche AG Tumor Immunity Therapy Introduction
11.3.4 Roche AG Revenue in Tumor Immunity Therapy Business (2018-2023)
11.3.5 Roche AG Recent Development
11.4 AstraZeneca, Plc
11.4.1 AstraZeneca, Plc Company Detail
11.4.2 AstraZeneca, Plc Business Overview
11.4.3 AstraZeneca, Plc Tumor Immunity Therapy Introduction
11.4.4 AstraZeneca, Plc Revenue in Tumor Immunity Therapy Business (2018-2023)
11.4.5 AstraZeneca, Plc Recent Development
11.5 Sanofi S.A.
11.5.1 Sanofi S.A. Company Detail
11.5.2 Sanofi S.A. Business Overview
11.5.3 Sanofi S.A. Tumor Immunity Therapy Introduction
11.5.4 Sanofi S.A. Revenue in Tumor Immunity Therapy Business (2018-2023)
11.5.5 Sanofi S.A. Recent Development
11.6 Dendreon Pharmaceuticals
11.6.1 Dendreon Pharmaceuticals Company Detail
11.6.2 Dendreon Pharmaceuticals Business Overview
11.6.3 Dendreon Pharmaceuticals Tumor Immunity Therapy Introduction
11.6.4 Dendreon Pharmaceuticals Revenue in Tumor Immunity Therapy Business (2018-2023)
11.6.5 Dendreon Pharmaceuticals Recent Development
11.7 Novartis
11.7.1 Novartis Company Detail
11.7.2 Novartis Business Overview
11.7.3 Novartis Tumor Immunity Therapy Introduction
11.7.4 Novartis Revenue in Tumor Immunity Therapy Business (2018-2023)
11.7.5 Novartis Recent Development
11.8 Gilead Sciences Inc.
11.8.1 Gilead Sciences Inc. Company Detail
11.8.2 Gilead Sciences Inc. Business Overview
11.8.3 Gilead Sciences Inc. Tumor Immunity Therapy Introduction
11.8.4 Gilead Sciences Inc. Revenue in Tumor Immunity Therapy Business (2018-2023)
11.8.5 Gilead Sciences Inc. Recent Development
11.9 IMVAQ Therapeutics
11.9.1 IMVAQ Therapeutics Company Detail
11.9.2 IMVAQ Therapeutics Business Overview
11.9.3 IMVAQ Therapeutics Tumor Immunity Therapy Introduction
11.9.4 IMVAQ Therapeutics Revenue in Tumor Immunity Therapy Business (2018-2023)
11.9.5 IMVAQ Therapeutics Recent Development
11.10 Arch Oncology
11.10.1 Arch Oncology Company Detail
11.10.2 Arch Oncology Business Overview
11.10.3 Arch Oncology Tumor Immunity Therapy Introduction
11.10.4 Arch Oncology Revenue in Tumor Immunity Therapy Business (2018-2023)
11.10.5 Arch Oncology Recent Development
11.11 Juno Therapeutics
11.11.1 Juno Therapeutics Company Detail
11.11.2 Juno Therapeutics Business Overview
11.11.3 Juno Therapeutics Tumor Immunity Therapy Introduction
11.11.4 Juno Therapeutics Revenue in Tumor Immunity Therapy Business (2018-2023)
11.11.5 Juno Therapeutics Recent Development
11.12 Refuge
11.12.1 Refuge Company Detail
11.12.2 Refuge Business Overview
11.12.3 Refuge Tumor Immunity Therapy Introduction
11.12.4 Refuge Revenue in Tumor Immunity Therapy Business (2018-2023)
11.12.5 Refuge Recent Development
11.13 Lepu Biopharma
11.13.1 Lepu Biopharma Company Detail
11.13.2 Lepu Biopharma Business Overview
11.13.3 Lepu Biopharma Tumor Immunity Therapy Introduction
11.13.4 Lepu Biopharma Revenue in Tumor Immunity Therapy Business (2018-2023)
11.13.5 Lepu Biopharma Recent Development
11.14 Genoimmune
11.14.1 Genoimmune Company Detail
11.14.2 Genoimmune Business Overview
11.14.3 Genoimmune Tumor Immunity Therapy Introduction
11.14.4 Genoimmune Revenue in Tumor Immunity Therapy Business (2018-2023)
11.14.5 Genoimmune Recent Development
11.15 TCR Cure
11.15.1 TCR Cure Company Detail
11.15.2 TCR Cure Business Overview
11.15.3 TCR Cure Tumor Immunity Therapy Introduction
11.15.4 TCR Cure Revenue in Tumor Immunity Therapy Business (2018-2023)
11.15.5 TCR Cure Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Tumor Immunity Therapy Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Immune Checkpoint Inhibitor
Table 3. Key Players of Cytokine Immunotherapy
Table 4. Key Players of Cancer Vaccine
Table 5. Key Players of Car-t Cell Therapy
Table 6. Key Players of Others
Table 7. Global Tumor Immunity Therapy Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Tumor Immunity Therapy Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global Tumor Immunity Therapy Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Tumor Immunity Therapy Market Share by Region (2018-2023)
Table 11. Global Tumor Immunity Therapy Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 12. Global Tumor Immunity Therapy Market Share by Region (2024-2029)
Table 13. Tumor Immunity Therapy Market Trends
Table 14. Tumor Immunity Therapy Market Drivers
Table 15. Tumor Immunity Therapy Market Challenges
Table 16. Tumor Immunity Therapy Market Restraints
Table 17. Global Tumor Immunity Therapy Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Tumor Immunity Therapy Market Share by Players (2018-2023)
Table 19. Global Top Tumor Immunity Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunity Therapy as of 2022)
Table 20. Ranking of Global Top Tumor Immunity Therapy Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Tumor Immunity Therapy Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Tumor Immunity Therapy Product Solution and Service
Table 24. Date of Enter into Tumor Immunity Therapy Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Tumor Immunity Therapy Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Tumor Immunity Therapy Revenue Market Share by Type (2018-2023)
Table 28. Global Tumor Immunity Therapy Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 29. Global Tumor Immunity Therapy Revenue Market Share by Type (2024-2029)
Table 30. Global Tumor Immunity Therapy Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Tumor Immunity Therapy Revenue Market Share by Application (2018-2023)
Table 32. Global Tumor Immunity Therapy Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 33. Global Tumor Immunity Therapy Revenue Market Share by Application (2024-2029)
Table 34. North America Tumor Immunity Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. North America Tumor Immunity Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 36. North America Tumor Immunity Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 37. Europe Tumor Immunity Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. Europe Tumor Immunity Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 39. Europe Tumor Immunity Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 40. Asia-Pacific Tumor Immunity Therapy Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 41. Asia-Pacific Tumor Immunity Therapy Market Size by Region (2018-2023) & (US$ Million)
Table 42. Asia-Pacific Tumor Immunity Therapy Market Size by Region (2024-2029) & (US$ Million)
Table 43. Latin America Tumor Immunity Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Latin America Tumor Immunity Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 45. Latin America Tumor Immunity Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 46. Middle East & Africa Tumor Immunity Therapy Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 47. Middle East & Africa Tumor Immunity Therapy Market Size by Country (2018-2023) & (US$ Million)
Table 48. Middle East & Africa Tumor Immunity Therapy Market Size by Country (2024-2029) & (US$ Million)
Table 49. Bristol-Myers Squibb Company Detail
Table 50. Bristol-Myers Squibb Business Overview
Table 51. Bristol-Myers Squibb Tumor Immunity Therapy Product
Table 52. Bristol-Myers Squibb Revenue in Tumor Immunity Therapy Business (2018-2023) & (US$ Million)
Table 53. Bristol-Myers Squibb Recent Development
Table 54. Merck & Co., Inc. Company Detail
Table 55. Merck & Co., Inc. Business Overview
Table 56. Merck & Co., Inc. Tumor Immunity Therapy Product
Table 57. Merck & Co., Inc. Revenue in Tumor Immunity Therapy Business (2018-2023) & (US$ Million)
Table 58. Merck & Co., Inc. Recent Development
Table 59. Roche AG Company Detail
Table 60. Roche AG Business Overview
Table 61. Roche AG Tumor Immunity Therapy Product
Table 62. Roche AG Revenue in Tumor Immunity Therapy Business (2018-2023) & (US$ Million)
Table 63. Roche AG Recent Development
Table 64. AstraZeneca, Plc Company Detail
Table 65. AstraZeneca, Plc Business Overview
Table 66. AstraZeneca, Plc Tumor Immunity Therapy Product
Table 67. AstraZeneca, Plc Revenue in Tumor Immunity Therapy Business (2018-2023) & (US$ Million)
Table 68. AstraZeneca, Plc Recent Development
Table 69. Sanofi S.A. Company Detail
Table 70. Sanofi S.A. Business Overview
Table 71. Sanofi S.A. Tumor Immunity Therapy Product
Table 72. Sanofi S.A. Revenue in Tumor Immunity Therapy Business (2018-2023) & (US$ Million)
Table 73. Sanofi S.A. Recent Development
Table 74. Dendreon Pharmaceuticals Company Detail
Table 75. Dendreon Pharmaceuticals Business Overview
Table 76. Dendreon Pharmaceuticals Tumor Immunity Therapy Product
Table 77. Dendreon Pharmaceuticals Revenue in Tumor Immunity Therapy Business (2018-2023) & (US$ Million)
Table 78. Dendreon Pharmaceuticals Recent Development
Table 79. Novartis Company Detail
Table 80. Novartis Business Overview
Table 81. Novartis Tumor Immunity Therapy Product
Table 82. Novartis Revenue in Tumor Immunity Therapy Business (2018-2023) & (US$ Million)
Table 83. Novartis Recent Development
Table 84. Gilead Sciences Inc. Company Detail
Table 85. Gilead Sciences Inc. Business Overview
Table 86. Gilead Sciences Inc. Tumor Immunity Therapy Product
Table 87. Gilead Sciences Inc. Revenue in Tumor Immunity Therapy Business (2018-2023) & (US$ Million)
Table 88. Gilead Sciences Inc. Recent Development
Table 89. IMVAQ Therapeutics Company Detail
Table 90. IMVAQ Therapeutics Business Overview
Table 91. IMVAQ Therapeutics Tumor Immunity Therapy Product
Table 92. IMVAQ Therapeutics Revenue in Tumor Immunity Therapy Business (2018-2023) & (US$ Million)
Table 93. IMVAQ Therapeutics Recent Development
Table 94. Arch Oncology Company Detail
Table 95. Arch Oncology Business Overview
Table 96. Arch Oncology Tumor Immunity Therapy Product
Table 97. Arch Oncology Revenue in Tumor Immunity Therapy Business (2018-2023) & (US$ Million)
Table 98. Arch Oncology Recent Development
Table 99. Juno Therapeutics Company Detail
Table 100. Juno Therapeutics Business Overview
Table 101. Juno Therapeutics Tumor Immunity Therapy Product
Table 102. Juno Therapeutics Revenue in Tumor Immunity Therapy Business (2018-2023) & (US$ Million)
Table 103. Juno Therapeutics Recent Development
Table 104. Refuge Company Detail
Table 105. Refuge Business Overview
Table 106. Refuge Tumor Immunity Therapy Product
Table 107. Refuge Revenue in Tumor Immunity Therapy Business (2018-2023) & (US$ Million)
Table 108. Refuge Recent Development
Table 109. Lepu Biopharma Company Detail
Table 110. Lepu Biopharma Business Overview
Table 111. Lepu Biopharma Tumor Immunity Therapy Product
Table 112. Lepu Biopharma Revenue in Tumor Immunity Therapy Business (2018-2023) & (US$ Million)
Table 113. Lepu Biopharma Recent Development
Table 114. Genoimmune Company Detail
Table 115. Genoimmune Business Overview
Table 116. Genoimmune Tumor Immunity Therapy Product
Table 117. Genoimmune Revenue in Tumor Immunity Therapy Business (2018-2023) & (US$ Million)
Table 118. Genoimmune Recent Development
Table 119. TCR Cure Company Detail
Table 120. TCR Cure Business Overview
Table 121. TCR Cure Tumor Immunity Therapy Product
Table 122. TCR Cure Revenue in Tumor Immunity Therapy Business (2018-2023) & (US$ Million)
Table 123. TCR Cure Recent Development
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Tumor Immunity Therapy Market Size Comparison by Type (2023-2029) & (US$ Million)
Figure 2. Global Tumor Immunity Therapy Market Share by Type: 2022 VS 2029
Figure 3. Immune Checkpoint Inhibitor Features
Figure 4. Cytokine Immunotherapy Features
Figure 5. Cancer Vaccine Features
Figure 6. Car-t Cell Therapy Features
Figure 7. Others Features
Figure 8. Global Tumor Immunity Therapy Market Size Comparison by Application (2023-2029) & (US$ Million)
Figure 9. Global Tumor Immunity Therapy Market Share by Application: 2022 VS 2029
Figure 10. Hospital Case Studies
Figure 11. Clinic Case Studies
Figure 12. Tumor Immunity Therapy Report Years Considered
Figure 13. Global Tumor Immunity Therapy Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 14. Global Tumor Immunity Therapy Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 15. Global Tumor Immunity Therapy Market Share by Region: 2022 VS 2029
Figure 16. Global Tumor Immunity Therapy Market Share by Players in 2022
Figure 17. Global Top Tumor Immunity Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immunity Therapy as of 2022)
Figure 18. The Top 10 and 5 Players Market Share by Tumor Immunity Therapy Revenue in 2022
Figure 19. North America Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 20. North America Tumor Immunity Therapy Market Share by Country (2018-2029)
Figure 21. United States Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. Canada Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. Europe Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Europe Tumor Immunity Therapy Market Share by Country (2018-2029)
Figure 25. Germany Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. France Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. U.K. Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Italy Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. Russia Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Nordic Countries Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Asia-Pacific Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Asia-Pacific Tumor Immunity Therapy Market Share by Region (2018-2029)
Figure 33. China Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Japan Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. South Korea Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Southeast Asia Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. India Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Australia Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. Latin America Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Latin America Tumor Immunity Therapy Market Share by Country (2018-2029)
Figure 41. Mexico Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Brazil Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 43. Middle East & Africa Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Middle East & Africa Tumor Immunity Therapy Market Share by Country (2018-2029)
Figure 45. Turkey Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Saudi Arabia Tumor Immunity Therapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. Bristol-Myers Squibb Revenue Growth Rate in Tumor Immunity Therapy Business (2018-2023)
Figure 48. Merck & Co., Inc. Revenue Growth Rate in Tumor Immunity Therapy Business (2018-2023)
Figure 49. Roche AG Revenue Growth Rate in Tumor Immunity Therapy Business (2018-2023)
Figure 50. AstraZeneca, Plc Revenue Growth Rate in Tumor Immunity Therapy Business (2018-2023)
Figure 51. Sanofi S.A. Revenue Growth Rate in Tumor Immunity Therapy Business (2018-2023)
Figure 52. Dendreon Pharmaceuticals Revenue Growth Rate in Tumor Immunity Therapy Business (2018-2023)
Figure 53. Novartis Revenue Growth Rate in Tumor Immunity Therapy Business (2018-2023)
Figure 54. Gilead Sciences Inc. Revenue Growth Rate in Tumor Immunity Therapy Business (2018-2023)
Figure 55. IMVAQ Therapeutics Revenue Growth Rate in Tumor Immunity Therapy Business (2018-2023)
Figure 56. Arch Oncology Revenue Growth Rate in Tumor Immunity Therapy Business (2018-2023)
Figure 57. Juno Therapeutics Revenue Growth Rate in Tumor Immunity Therapy Business (2018-2023)
Figure 58. Refuge Revenue Growth Rate in Tumor Immunity Therapy Business (2018-2023)
Figure 59. Lepu Biopharma Revenue Growth Rate in Tumor Immunity Therapy Business (2018-2023)
Figure 60. Genoimmune Revenue Growth Rate in Tumor Immunity Therapy Business (2018-2023)
Figure 61. TCR Cure Revenue Growth Rate in Tumor Immunity Therapy Business (2018-2023)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 免疫細胞療法の世界市場2023年：T細胞療法、ナチュラルキラー（NK）細胞療法、その他
  • mRNAプラットフォームの世界市場2023年：感染症ワクチン、がんワクチン
  • 腎臓がん治療薬のグローバル市場展望 2023年-2029年：血管新生阻害剤、mTOR阻害剤、モノクローナル抗体、サイトカイン免疫療法（IL-2）
  • mRNAプラットフォームのグローバル市場展望 2023年-2029年：感染症ワクチン、がんワクチン
  • 免疫ケアサプリメントの世界市場2023年：カプセル状、粉末状、液体状、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(QYR23MA8914 )"腫瘍免疫治療の世界市場2023年：免疫チェックポイント阻害剤、サイトカイン免疫療法、がんワクチン、Car-t細胞療法、その他" (英文：Global Tumor Immunity Therapy Market Research Report 2023)はQYResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。